Choice Institutional Equities rates Narayana Health a Buy with a Rs 2,500 target
Choice Institutional Equities keeps a Buy rating on Narayana Health with a Rs 2,500 target price and revises its EBITDA forecast for the UK integration.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Choice Institutional Equities, as reported by TradingView, Narayana Health still has room for steady growth. Its integrated model, which combines hospitals, outpatient clinics and insurance in India, keeps expanding, while profitability in the Cayman Islands is improving. The company is also restructuring its operations in the UK.
The analysts expect revenue, EBITDA and adjusted net profit (APAT) to grow at compound annual rates of 22.3%, 22.3% and 29.5% respectively over FY26–FY29E. The target price stays at Rs 2,500 with a Buy rating. The valuation rests on 20x EV/EBITDA, averaged over FY28–FY29E. The EBITDA estimate has been revised to account for the UK business integration.
why it matters
For the market, this is a single brokerage report rather than an event with sector-wide reach. It matters most to investors tracking Indian hospital groups, and it shows how folding in the UK assets changes the company's valuation model. Reports like this typically have little effect on the broader market.
tags
instruments
sources
- Buy Narayana Health; target of Rs 2500: Choice Institutional Equities — TradingView, 3 November 2026 at 05:25 UTC
- Buy Birla Corporation; target of Rs 1125: Choice Institutional Equities — TradingView, 3 November 2026 at 05:32 UTC
- Buy Rainbow Childrens; target of Rs 1650: Choice Institutional Equities — TradingView, 3 November 2026 at 05:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗